A review of triple-negative breast cancer

Cancer Control

Volumn 17, Issue 3, 2010, Pages 173-176

  Ismail Khan, Roohi ^a   Bui, Marilyn M ^a  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; BRCA1 PROTEIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 1; PACLITAXEL; PROGESTERONE RECEPTOR;

ARTICLE; BONE METASTASIS; BRAIN METASTASIS; BREAST CANCER; CANCER ADJUVANT THERAPY; CLINICAL FEATURE; DISEASE COURSE; HUMAN; LIVER METASTASIS; LUNG METASTASIS; PROGNOSIS; PROGRESSION FREE SURVIVAL; TRIPLE NEGATIVE BREAST CANCER; VISCERAL METASTASIS;

EID: 77955010884     PISSN: 10732748     EISSN: 15262359     Source Type: Journal    
DOI: 10.1177/107327481001700305     Document Type: Article

References (26)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2009. CA Cancer J Clin. 2009;59(4):225-249.
2. Kaplan HG, Malmgren JA., Atwood MK. Impact of triple negative phe-notype on breast cancer prognosis. Poster presented at: 29th Annual San Antonio Breast Cancer Symposium; December 14-17, 2006; San Antonio, TX.
3. Anders CK, Carey LA. Biology, metastatic patterns, and treatment of patients with triple-negative breast cancer. Clin Breast Cancer. 2009; 9(suppl 2): S73-S81.
4. Rakha EA, Reis-Filho JS, Ellis IO. Basal-like breast cancer: a critical review. J Clin Oncol. 2008;26(15):2568-2581.
5. Carey LA, Perou CM, Livasy CA, et al. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA. 2006; 295(21): 2492-2502.
6. Lakhani SR, Van De Vijver MJ, Jacquemier J, et al. The pathology of familial breast cancer: predictive value of immunohistochemical markers estrogen receptor, progesterone receptor, HER-2, and p53 in patients with mutations in BRCA1 and BRCA2. J Clin Oncol. 2002;20(9):2310-2318.
7. Sorlie T, Tibshirani R, Parker J, et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci U S A. 2003;100(14):8418-8423.
8. Perou CM, Sørlie T, Eisen MB, et al. Molecular portraits of human breast tumours. Nature. 2000;406(6797):747-752.
9. Sørlie T, Perou CM, Fan C, et al. Gene expression profiles do not consistently predict the clinical treatment response in locally advanced breast cancer. Mol Cancer Ther. 2006;5(11):2914-2918.
10. Sørlie T, Perou CM, Tibshirani R, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A. 2001;98(19):10869-10874.
11. Sørlie T, Wang Y, Xiao C, et al. Distinct molecular mechanisms underlying clinically relevant subtypes of breast cancer: gene expression analyses across three different platforms. BMC Genomics. 2006;7:127.
12. Rakha EA, El-Sayed ME, Green AR, et al. Prognostic markers in triple-negative breast cancer. Cancer. 2007;109(1):25-32.
13. Sotiriou C, Pusztai L. Gene-expression signatures in breast cancer. N Engl J Med. 2009;360(8):790-800.
14. Korsching E, Jeffrey SS, Meinerz W, et al. Basal carcinoma of the breast revisited: an old entity with new interpretations. J Clin Pathol. 2008; 61(5):553-560.
15. Mallon E, Osin P, Nasiri N, et al. The basic pathology of human breast cancer. J Mammary Gland Biol Neoplasia. 2000;5(2):139-163.
16. De Giorgi U, Rosti G, Frassineti L, et al. High-dose chemotherapy for triple negative breast cancer. Ann Oncol. 2007;18(1):202-203.
17. Kaplan HG, Malmgren JA, Atwood MK. T1N0 triple negative breast cancer: adjuvant chemotherapy treatment and risk of recurrence. Presented at the 30th Annual San Antonio Breast Cancer Symposium; December 13-16, 2007; San Antonio, TX. Abstract 3070.
18. Carey LA, Dees EC, Sawyer L, et al. The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. Clin Cancer Res. 2007;13(8):2329-2334.
19. Liedtke C, Mazouni C, Hess KR, et al. Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin Oncol. 2008;26(8):1275-1281.
20. Heitz F, Harter P, Traut A, et al. Cerebral metastases (CM) in breast cancer (BC) with focus on triple-negative tumors. Presented at the 44th Annual American Society of Clinical Oncology Meeting; May 30-June 3, 2008; Chicago, IL. J Clin Oncol. 2008; 26:(May 20 suppl). Abstract 1010.
21. Kaplan HG, Malmgren JA, Atwood M. T1N0 triple negative breast cancer: risk of recurrence and adjuvant chemotherapy. Breast J. 2009;15 (5):454-460.
22. Miller K, Wang M, Gralow J, et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med. 2007;357 (26):2666-2676.
23. Siziopikou KP, Cobleigh M. The basal subtype of breast carcinomas may represent the group of breast tumors that could benefit from EGFR-targeted therapies. Breast. 2007;16(1):104-107.
24. Rottenberg S, Jaspers JE, Kersbergen A, et al. High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs. Proc Natl Acad Sci U S A. 2008; 105(44):17079-17084.
25. Farmer H, McCabe N, Lord CJ, et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature. 2005; 434(7035): 917-921.
26. O'Shaughnessy J, Osborne C, Pippen J, et al. Efficacy of BSI-201, a poly (ADP-ribose) polymerase-1 (PARP1) inhibitor, in combination with gemcitabine/carboplatin (G/C) in patients with metastatic triple-negative breast cancer (TNBC): results of a randomized phase II trial. Presented at the 45th Annual American Society of Clinical Oncology Meeting; May 29-June 2, 2009; Orlando, FL. J Clin Oncol. 2009; 27:18s(suppl). Abstract 3.